ABS-101 / Amberstone Biosci - LARVOL DELTA

Phase 1 Study to Investigate ABS-101 in Healthy Adult Participants (ANZCTR) - P1 | N=40 | Recruiting | Sponsor: Absci Pty Ltd | Not yet recruiting ➔ Recruiting | Initiation date: May 2025

Enrollment open • Trial initiation date • Inflammation

Phase 1 Study to Investigate ABS-101 in Healthy Adult Participants (ANZCTR) - P1 | N=40 | Not yet recruiting | Sponsor: Absci Pty Ltd

New P1 trial • Inflammation

ABS-101, a novel class of tumor-activated CD3xTROP2 T cell engager for solid tumors (SITC 2024) - "Conclusions Preclinical results indicate that ABS-101 achieves a superior balance of safety and efficacy for solid tumor treatment. The T-MATE® therapeutic platform can be extended to additional TCEs and other modalities, offering a powerful and safe therapeutic approach for solid cancer indications."

Breast Cancer • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer